Core Insights - Unicycive Therapeutics, Inc. is participating in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025, where CEO Shalabh Gupta will engage in a fireside chat [1] - The company is focused on developing therapies for kidney diseases, with its lead investigational treatment, oxylanthanum carbonate, currently under FDA review for hyperphosphatemia in chronic kidney disease patients on dialysis [3] - Unicycive's second investigational treatment, UNI-494, is aimed at treating conditions related to acute kidney injury and has received orphan drug designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [3] Company Overview - Unicycive Therapeutics is a clinical-stage biotechnology company specializing in novel treatments for kidney diseases [3] - The company is developing oxylanthanum carbonate as a phosphate binding agent and has completed a Phase 1 safety study for UNI-494 [3] - More information about the company can be found on its website and social media platforms [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that Unicycive Therapeutics overstated its readiness to meet FDA manufacturing compliance requirements, as well as the regulatory prospects of its oxylanthanum carbonate new drug application [1]. - It is claimed that the public statements made by the defendants were materially false and misleading throughout the class period from March 29, 2024, to June 27, 2025 [1]. Class Action Details - Shareholders who purchased shares of UNCY during the class period are encouraged to register for the class action, with a deadline set for October 14, 2025 [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible business conduct [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Points - The Gross Law Firm is notifying shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit related to misleading statements made by the company during a specified period [1][3] - The class period for the lawsuit is from March 29, 2024, to June 27, 2025, during which the company allegedly overstated its compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [3] - Shareholders are encouraged to register for the class action by October 14, 2025, to potentially recover losses incurred due to the alleged misleading statements [4] Company Allegations - The complaint alleges that Unicycive's readiness to meet FDA manufacturing compliance was overstated [3] - It is claimed that the regulatory prospects for the oxylanthanum carbonate new drug application were also overstated [3] - As a result of these issues, the public statements made by the company were materially false and misleading throughout the relevant time [3] Next Steps for Shareholders - Shareholders who purchased shares during the class period can register to be monitored for updates on the case [4] - There is no cost or obligation for shareholders to participate in the class action [4] - The deadline to seek lead plaintiff status is October 14, 2025 [4]

Core Points - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit [1] - Shareholders who purchased shares during the class period from March 29, 2024, to June 27, 2025, are encouraged to contact the firm for possible lead plaintiff appointment [3][4] - Allegations include that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its new drug application [3] Class Action Details - The class period for the lawsuit is specified as March 29, 2024, to June 27, 2025 [3] - The deadline for shareholders to register for the class action is October 14, 2025 [4] - Shareholders will be enrolled in a portfolio monitoring software for status updates throughout the case lifecycle [4] Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5]

Core Viewpoint - Unicycive Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [2][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 29, 2024, to June 27, 2025 [2]. - Allegations include overstating Unicycive's readiness to meet FDA manufacturing compliance and the regulatory prospects of its oxylanthanum carbonate new drug application [2]. Group 2: Shareholder Actions - Shareholders who purchased UNCY shares during the class period are encouraged to register for the class action and can seek lead plaintiff status by the deadline of October 14, 2025 [3]. - Registration allows shareholders to receive updates through portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [4].

Core Viewpoint - Unicycive Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [3][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as March 29, 2024, to June 27, 2025 [3]. - Allegations include overstating Unicycive's readiness to meet FDA manufacturing compliance and the regulatory prospects of its oxylanthanum carbonate new drug application [3]. Group 2: Shareholder Actions - Shareholders who purchased UNCY shares during the class period are encouraged to register for the class action, with a deadline set for October 14, 2025 [4]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Insights - Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney disease [1][2] - The company will participate in two investor events in September 2025, including the H.C. Wainwright 27th Annual Global Investment Conference and a Truist Securities Virtual Fireside Chat [1] Company Overview - Unicycive's lead investigational treatment is oxylanthanum carbonate, a phosphate binding agent under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis [2] - The second investigational treatment, UNI-494, targets conditions related to acute kidney injury and has received orphan drug designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [2] - UNI-494 has completed a Phase 1 dose-ranging safety study in healthy volunteers [2]

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2] - It is also alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were exaggerated [2] - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3] - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Unicycive Therapeutics, Inc. about a class action lawsuit due to alleged misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 29, 2024, to June 27, 2025, Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [3]. - It is claimed that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [3]. - As a result, the public statements made by the defendants were materially false and misleading throughout the relevant time [3]. Group 2: Class Action Details - Shareholders who purchased shares of UNCY during the specified class period are encouraged to register for the class action, with a deadline set for October 14, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the specified class period [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 29, 2024, to June 27, 2025 [1]. - Allegations include that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by October 14, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].